Overview
Estimated glomerular filtration rate is a calculated estimate of kidney filtration derived from serum creatinine or cystatin C together with demographic variables. It is central to the detection, classification and monitoring of chronic kidney disease, but it is not a direct measurement and should never be interpreted in isolation. The most useful question is rarely “What is the eGFR today?” but rather “Is this result expected for this person, is it stable, and is there other evidence of kidney damage?”
Historical development
Early assessment relied on measured clearance of exogenous markers or timed urine creatinine clearance. These methods are cumbersome and vulnerable to collection error. Equations such as Cockcroft–Gault, MDRD and later CKD-EPI made routine estimation possible. More recent creatinine equations removed race coefficients and improved performance across broader populations. Cystatin C and combined creatinine–cystatin C equations now provide an important confirmatory option when creatinine is likely to be misleading.
What GFR represents
Glomerular filtration rate describes the volume of plasma filtered by the glomeruli per unit time, usually indexed to a standard body surface area of 1.73 square metres. True GFR varies with age, haemodynamics, pregnancy, diet, medications and acute illness. Indexing supports population comparison but may not reflect absolute drug clearance in people with very large or very small body size. The reported eGFR is therefore an estimate of a physiological process, not an exact measured quantity.
Creatinine-based equations
Serum creatinine reflects production from muscle and elimination, largely through glomerular filtration with some tubular secretion. Creatinine-based equations attempt to account for expected generation using age and sex. They perform reasonably in stable adults but become less reliable when creatinine production is unusual or renal function is changing rapidly. A value can appear reassuring in a frail person with very low muscle mass despite clinically important kidney dysfunction.
Cystatin C and combined equations
Cystatin C is produced by nucleated cells and is less dependent on muscle mass than creatinine. It can improve estimation when creatinine is uncertain and can help confirm chronic kidney disease in selected patients. However, cystatin C may be influenced by inflammation, thyroid dysfunction, corticosteroid exposure, smoking and other factors. Combined creatinine–cystatin C equations are often more accurate than either marker alone and are especially useful when decisions depend on a more precise estimate.
CKD classification
Chronic kidney disease is classified using GFR categories G1 to G5 and albuminuria categories A1 to A3. G1 and G2 do not establish CKD without another marker of kidney damage. Persistent eGFR below 60 mL/min/1.73 m² for at least three months generally meets the filtration criterion for CKD. Risk rises progressively as eGFR falls and albuminuria increases. The heat-map approach combines both dimensions and is more informative than either alone.
Albuminuria and urinalysis
Urine albumin-to-creatinine ratio is a powerful marker of glomerular damage and cardiovascular risk. It should accompany eGFR assessment in people at risk of CKD. Haematuria, proteinuria, casts and other urinalysis findings can point to specific disease. A normal eGFR does not exclude important kidney disease when albuminuria or structural abnormalities are present. Conversely, a mildly reduced eGFR in an older adult may carry different implications depending on albuminuria and trajectory.
Acute kidney injury
eGFR equations assume a steady creatinine state and should not be used to stage acute kidney injury. During rapidly changing renal function, serum creatinine lags behind the true change in filtration. A reported eGFR may therefore overestimate function during deterioration and underestimate recovery. Acute kidney injury is diagnosed using change in creatinine and urine output criteria, supported by clinical context. Medication and fluid decisions should reflect the dynamic state rather than a single calculated eGFR.
Population and body-composition limitations
Interpret cautiously in amputees, bodybuilders, people with paralysis, severe malnutrition, oedema, cirrhosis, advanced cancer and other states with unusual muscle mass. Pregnancy changes filtration and requires pregnancy-specific interpretation. Children use paediatric equations. At extremes of body size, indexed eGFR may need conversion to an absolute value for selected dosing decisions, but the relevant medicine guidance should be followed. No equation removes the need for clinical judgement.
Drug dosing
Many modern medicine recommendations use eGFR, while some product information still specifies creatinine clearance calculated by Cockcroft–Gault. The values are not automatically interchangeable. This matters for medicines with narrow therapeutic windows, direct oral anticoagulants, antimicrobials, cytotoxic agents and medicines with substantial renal elimination. Confirm which measure the dosing guidance requires, use a stable recent creatinine, consider body-weight selection and seek pharmacy advice when the result is close to a dosing threshold.
Interpreting change over time
Biological and analytical variation can produce modest fluctuations. A clinically meaningful decline should be confirmed and interpreted alongside hydration, blood pressure, intercurrent illness, medication changes and urinary findings. Rapid or sustained loss is more concerning than a stable long-term reduction. Review renin–angiotensin system blockers, diuretics, non-steroidal anti-inflammatory drugs and other relevant medicines, but do not stop beneficial treatment automatically without considering the expected haemodynamic effect and the whole clinical picture.
Clinical assessment pathway
Confirm chronicity using previous results. Measure urine ACR and blood pressure, review diabetes and cardiovascular risk, assess medication exposure and consider ultrasound or serological investigation when indicated. Look for red flags such as rapid decline, heavy proteinuria, active urinary sediment, resistant hypertension, electrolyte disturbance, anaemia or systemic features. Referral thresholds should follow local and national guidance, taking account of predicted kidney-failure risk where available.
Communication with patients
Explain that eGFR is an estimate and that one abnormal result does not always mean permanent kidney disease. Use trends and albuminuria to frame risk. Avoid language that causes unnecessary alarm while being clear about modifiable factors such as blood-pressure control, diabetes management, smoking cessation and avoidance of nephrotoxins. Shared decision-making is especially important when discussing medication changes, contrast studies, referral or preparation for kidney replacement therapy.
Frequently asked questions
Is eGFR the same as creatinine clearance?
No. They use different equations and may support different decisions.
Can CKD exist with eGFR above 60?
Yes, when albuminuria, structural disease or another marker of kidney damage persists.
Why can eGFR change after starting an ACE inhibitor?
A haemodynamic fall may occur; the size, timing and clinical context determine whether it is acceptable.
When is cystatin C helpful?
When creatinine is likely to misrepresent filtration or a more precise estimate would change management.
Key points for practice
- Interpret eGFR with albuminuria, urinalysis and trend.
- Do not use steady-state equations to stage acute kidney injury.
- Recognise body-composition and population limitations.
- Use the renal measure specified by medicine guidance.
- Confirm chronicity before diagnosing CKD.
- Escalate rapid decline or high-risk features promptly.
Clinical pearls and professional practice
Use the result to answer a clearly defined clinical question. Calculations and thresholds are most useful when they are embedded in a structured assessment that includes history, examination, baseline risk, time course and response to treatment. A result should change a decision, refine a differential diagnosis or prompt monitoring; otherwise, repeating it without a plan may add noise rather than value.
When handing over care, communicate the actual value, the relevant reference interval or threshold, the trend and the interpretation. Avoid shorthand that can be misunderstood by another team. Where local protocols differ from a general reference, the local validated pathway takes precedence. Document uncertainty explicitly and identify what subsequent finding would confirm or refute the working diagnosis.
Equity and population context also matter. Diagnostic equations and thresholds may perform differently at age extremes, in pregnancy, in people with unusual body composition and in populations under-represented in validation studies. Clinicians should recognise these limitations without withholding appropriate investigation. Specialist or laboratory advice is valuable when a result does not fit the clinical picture.
Quality and safety checklist
- Confirm patient identity, sample timing and measurement method.
- Check units and the local reference interval.
- Compare with previous values and the clinical trajectory.
- Review medicines, comorbidities and reversible factors.
- Look for conditions in which the test or equation is unreliable.
- Record the interpretation, action and follow-up plan.
- Escalate immediately when the patient is unstable, regardless of a reassuring calculation.
Clinical interpretation should remain proportionate to the decision being made. Reassess when new information becomes available, and avoid allowing a single numerical result to outweigh clear evidence of deterioration or an alternative diagnosis. Multidisciplinary discussion improves safety when treatment carries substantial benefit and risk.
Interpreting eGFR alongside albuminuria
Chronic kidney disease risk is not defined by eGFR alone. Albuminuria provides independent prognostic information and should be considered with the G category, age, comorbidity and rate of change. A person with preserved filtration but substantial albuminuria may have important kidney disease, while a stable mildly reduced eGFR in an older adult may carry a different risk profile. The KDIGO heat-map approach combines filtration and albumin categories to communicate risk and guide monitoring intensity.
Confirming chronicity and identifying acute change
A single reduced eGFR does not establish chronic kidney disease. Chronicity generally requires persistence for at least three months or other evidence of longstanding structural or functional abnormality. Review previous creatinine values, urine findings, imaging and clinical history. During acute illness, serum creatinine may be changing too rapidly for a steady-state equation to represent true filtration, so trend, urine output and the broader clinical picture become more important.
Creatinine, cystatin C and discordant estimates
Creatinine-based equations are influenced by muscle mass, diet, amputation, cachexia, body building and medicines that alter tubular secretion. Cystatin C can improve estimation where creatinine is likely to be misleading, although it has its own non-GFR determinants. When estimates are discordant, consider why and use the value most appropriate to the decision. Confirmatory testing may be particularly valuable near thresholds for drug dosing, contrast decisions, referral or kidney donation assessment.
Medication dosing and indexed values
Laboratories usually report eGFR indexed to a body surface area of 1.73 square metres. Some medication decisions require an absolute rather than indexed filtration estimate, especially at extremes of body size. Product information and local pharmacy guidance should determine the method used. Do not automatically substitute eGFR for creatinine clearance in every dosing recommendation, because validation and regulatory labelling vary between medicines.
Monitoring progression
Interpret change over a clinically meaningful interval and account for biological and analytical variation. A small fluctuation does not necessarily represent progression. Sustained decline, a substantial fall after an intervention, rapidly increasing albuminuria or associated haematuria warrants review. Consider haemodynamic effects, obstruction, nephrotoxins, intercurrent illness and renovascular disease where appropriate. Risk prediction tools may help determine referral and follow-up in selected adults with established chronic kidney disease.
Communication with patients and teams
Explain that eGFR is an estimate and that trends and urine markers matter. Avoid describing kidney function as a simple percentage, which can overstate precision. Document the equation, the suspected limitations and the action taken. Shared decisions should reflect cardiovascular risk, frailty, treatment burden and the person’s priorities as well as the numerical category.